Astellas Pharma Inc. (ALPMF)
USD 10.12
(0.0%)
USD 10.12
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 1005.71 Billion JPY | 402.84% |
| 2023 | 200 Billion JPY | -5.99% |
| 2022 | 212.74 Billion JPY | -23.55% |
| 2021 | 278.26 Billion JPY | -32.68% |
| 2020 | 413.33 Billion JPY | 34373.06% |
| 2019 | 1.19 Billion JPY | -11.05% |
| 2018 | 1.34 Billion JPY | -17.55% |
| 2017 | 1.63 Billion JPY | 33.25% |
| 2016 | 1.22 Billion JPY | 71.37% |
| 2015 | 716 Million JPY | -11.93% |
| 2014 | 813 Million JPY | 10.31% |
| 2013 | 737 Million JPY | 0.0% |
| 2012 | - JPY | 0.0% |
| 2011 | - JPY | 0.0% |
| 2010 | - JPY | 0.0% |
| 2009 | - JPY | 0.0% |
| 2008 | - JPY | -100.0% |
| 2007 | 1.67 Billion JPY | 71.21% |
| 2006 | 976 Million JPY | -80.56% |
| 2005 | 5.02 Billion JPY | -37.74% |
| 2004 | 8.06 Billion JPY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q4 | 1005.71 Billion JPY | 15.47% |
| 2024 Q1 | 359 Billion JPY | 79.49% |
| 2024 Q2 | 889.61 Billion JPY | 147.8% |
| 2024 FY | 1005.71 Billion JPY | 402.84% |
| 2024 Q3 | 870.98 Billion JPY | -2.09% |
| 2023 FY | 200 Billion JPY | -5.99% |
| 2023 Q3 | 148.73 Billion JPY | 80.53% |
| 2023 Q2 | 82.39 Billion JPY | -26.19% |
| 2023 Q1 | 111.62 Billion JPY | -47.53% |
| 2023 Q4 | 200 Billion JPY | 34.47% |
| 2022 FY | 212.74 Billion JPY | -23.55% |
| 2022 Q4 | 212.74 Billion JPY | 5.56% |
| 2022 Q3 | 201.53 Billion JPY | -1.61% |
| 2022 Q2 | 204.83 Billion JPY | 1.73% |
| 2022 Q1 | 201.36 Billion JPY | -27.64% |
| 2021 FY | 278.26 Billion JPY | -32.68% |
| 2021 Q3 | 1.24 Billion JPY | -54.66% |
| 2021 Q1 | 2.82 Billion JPY | -99.29% |
| 2021 Q4 | 278.26 Billion JPY | 22232.58% |
| 2021 Q2 | 2.74 Billion JPY | -2.62% |
| 2020 Q4 | 398.36 Billion JPY | 12534.6% |
| 2020 Q1 | 1.59 Billion JPY | -31.78% |
| 2020 FY | 413.33 Billion JPY | 34373.06% |
| 2020 Q2 | 2.96 Billion JPY | 85.72% |
| 2020 Q3 | 3.15 Billion JPY | 6.3% |
| 2019 Q3 | 1.57 Billion JPY | -59.4% |
| 2019 FY | 1.19 Billion JPY | -11.05% |
| 2019 Q4 | 2.34 Billion JPY | 48.92% |
| 2019 Q1 | 3.5 Billion JPY | -20.75% |
| 2019 Q2 | 3.87 Billion JPY | 10.57% |
| 2018 Q2 | 3.76 Billion JPY | -0.21% |
| 2018 Q1 | 3.76 Billion JPY | 139.09% |
| 2018 Q3 | 3.76 Billion JPY | 0.03% |
| 2018 Q4 | 4.41 Billion JPY | 17.5% |
| 2018 FY | 1.34 Billion JPY | -17.55% |
| 2017 FY | 1.63 Billion JPY | 33.25% |
| 2017 Q4 | 1.57 Billion JPY | 87.17% |
| 2017 Q3 | 842 Million JPY | -3.11% |
| 2017 Q2 | 869 Million JPY | -24.96% |
| 2017 Q1 | 1.15 Billion JPY | -50.11% |
| 2016 FY | 1.22 Billion JPY | 71.37% |
| 2016 Q2 | 1.75 Billion JPY | 89.41% |
| 2016 Q1 | 925 Million JPY | 29.19% |
| 2016 Q4 | 2.32 Billion JPY | 35.49% |
| 2016 Q3 | 1.71 Billion JPY | -2.23% |
| 2015 Q1 | 72 Million JPY | -91.14% |
| 2015 Q4 | 716 Million JPY | 695.56% |
| 2015 Q2 | 72 Million JPY | 0.0% |
| 2015 FY | 716 Million JPY | -11.93% |
| 2015 Q3 | 90 Million JPY | 25.0% |
| 2014 Q1 | - JPY | -100.0% |
| 2014 FY | 813 Million JPY | 10.31% |
| 2014 Q3 | - JPY | 0.0% |
| 2014 Q4 | 813 Million JPY | 0.0% |
| 2014 Q2 | - JPY | 0.0% |
| 2013 Q4 | 737 Million JPY | 0.0% |
| 2013 Q1 | - JPY | 0.0% |
| 2013 FY | 737 Million JPY | 0.0% |
| 2013 Q3 | - JPY | 0.0% |
| 2013 Q2 | - JPY | 0.0% |
| 2012 FY | - JPY | 0.0% |
| 2012 Q1 | - JPY | 0.0% |
| 2012 Q2 | - JPY | 0.0% |
| 2012 Q3 | - JPY | 0.0% |
| 2012 Q4 | - JPY | 0.0% |
| 2011 Q4 | - JPY | 0.0% |
| 2011 FY | - JPY | 0.0% |
| 2011 Q1 | 67.57 Billion JPY | 0.0% |
| 2011 Q2 | 30 Billion JPY | -55.6% |
| 2011 Q3 | - JPY | -100.0% |
| 2010 FY | - JPY | 0.0% |
| 2010 Q4 | - JPY | 0.0% |
| 2010 Q3 | - JPY | 0.0% |
| 2010 Q2 | - JPY | 0.0% |
| 2009 FY | - JPY | 0.0% |
| 2009 Q4 | - JPY | 0.0% |
| 2008 FY | - JPY | -100.0% |
| 2007 FY | 1.67 Billion JPY | 71.21% |
| 2006 FY | 976 Million JPY | -80.56% |
| 2005 FY | 5.02 Billion JPY | -37.74% |
| 2004 FY | 8.06 Billion JPY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AstraZeneca PLC | 28.58 Billion USD | -3418.755% |
| Bristol-Myers Squibb Company PFD CONV 2 | 41.46 Billion USD | -2325.516% |
| CSPC Pharmaceutical Group Limited | 99.64 Million USD | -1009189.136% |
| Clarus Therapeutics Holdings, Inc. | 42.26 Million USD | -2379222.908% |
| Novartis AG | 26.34 Billion USD | -3717.049% |
| PT Kalbe Farma Tbk. | 40.4 Million USD | -2488940.92% |